Published in PLoS One on August 20, 2013
Intra- and Inter-Tumoral Homogeneity of BRAF(V600E) Mutations in Melanoma Tumors. J Invest Dermatol (2015) 2.18
BRAF and NRAS mutations are heterogeneous and not mutually exclusive in nodular melanoma. Appl Immunohistochem Mol Morphol (2015) 1.47
BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. Onco Targets Ther (2015) 0.99
Detection of BRAF mutation in Chinese tumor patients using a highly sensitive antibody immunohistochemistry assay. Sci Rep (2015) 0.87
NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas. Diagn Pathol (2015) 0.87
High-resolution melting analysis for accurate detection of BRAF mutations: a systematic review and meta-analysis. Sci Rep (2014) 0.85
Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors. Oncotarget (2016) 0.83
PLCG1 Gene Mutations Are Uncommon in Cutaneous T-Cell Lymphomas. J Invest Dermatol (2015) 0.82
Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms. Am J Cancer Res (2015) 0.79
Intra-patient heterogeneity of BRAF mutation status: fact or fiction? Br J Cancer (2013) 0.78
Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma. Oncotarget (2015) 0.77
Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Hum Pathol (2015) 0.77
SNPase-ARMS qPCR: Ultrasensitive Mutation-Based Detection of Cell-Free Tumor DNA in Melanoma Patients. PLoS One (2015) 0.76
BRAFV600E immunopositive melanomas show low frequency of heterogeneity and association with epithelioid tumor cells: a STROBE-compliant article. Medicine (Baltimore) (2014) 0.76
Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients? BMC Cancer (2016) 0.75
Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry. Oncotarget (2016) 0.75
A UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma. Br J Cancer (2016) 0.75
Reply: Intra-patient heterogeneity of BRAF mutation status: fact or fiction? Br J Cancer (2014) 0.75
Intratumor and Intertumor Heterogeneity in Melanoma. Transl Oncol (2017) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69
Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature (2010) 15.63
Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin (2012) 14.47
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
High frequency of BRAF mutations in nevi. Nat Genet (2002) 9.95
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol (2011) 7.18
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol (1999) 5.95
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71
The MAPK pathway in melanoma. Curr Opin Oncol (2008) 2.80
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med (2010) 2.65
Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res (2007) 2.62
Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol (2011) 2.53
Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas. J Mol Diagn (2012) 2.53
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov (2012) 2.48
BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol (2012) 2.41
Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma. PLoS One (2012) 2.40
Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol (2003) 2.14
Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol (2011) 2.09
Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol (2011) 1.91
Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn (2007) 1.85
Melanoma incidence and mortality in Europe: new estimates, persistent disparities. Br J Dermatol (2012) 1.83
Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol (2013) 1.80
Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression. Br J Cancer (2011) 1.73
Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn (2012) 1.66
Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma. Arch Pathol Lab Med (2012) 1.64
NRAS and BRAF mutations in cutaneous melanoma and the association with MC1R genotype: findings from Spanish and Austrian populations. J Invest Dermatol (2012) 1.49
A new method to extract nuclei from paraffin-embedded tissue to study lymphomas using interphase fluorescence in situ hybridization. Am J Pathol (2002) 1.32
Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions. Am J Surg Pathol (2013) 1.17
Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther (2012) 1.16
Detection of BRAF V600E mutation by pyrosequencing. Pathology (2008) 1.16
Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. Ann Oncol (2012) 1.12
Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1. J Am Acad Dermatol (2012) 1.09
Impact of mutation type and amplicon characteristics on genetic diversity measures generated using a high-resolution melting diversity assay. J Mol Diagn (2012) 1.08
BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma. Br J Cancer (2013) 1.08
Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma. Mod Pathol (2012) 1.02
Molecular platforms utilized to detect BRAF V600E mutation in melanoma. Semin Cutan Med Surg (2012) 1.01
BRAF mutation analysis of only one metastatic lesion can restrict the treatment of melanoma: a case report. Br J Dermatol (2012) 1.01
BRAF inhibitor activity in V600R metastatic melanoma--response. Eur J Cancer (2013) 0.81
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N Engl J Med (2010) 2.47
Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol (2005) 2.15
Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol (2007) 2.00
Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat (2011) 1.89
Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet (2012) 1.81
Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma by array-based comparative genomic hybridization. Haematologica (2008) 1.80
Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis (2005) 1.54
Fluorescence in situ hybridization, a diagnostic aid in ambiguous melanocytic tumors: European study of 113 cases. Mod Pathol (2010) 1.52
Segmental vitiligo associated with generalized vitiligo (mixed vitiligo): a retrospective case series of 19 patients. J Am Acad Dermatol (2011) 1.48
Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. J Thorac Oncol (2014) 1.41
Endometrial brush cytology in the surveillance of post-menopausal patients under tamoxifen: a prospective longitudinal study. Eur J Obstet Gynecol Reprod Biol (2006) 1.38
Netrin-1 acts as a survival factor for aggressive neuroblastoma. J Exp Med (2009) 1.36
Common variants in FOXP1 are associated with generalized vitiligo. Nat Genet (2010) 1.25
Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. Blood (2009) 1.16
Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay. J Transl Med (2004) 1.15
Comprehensive association analysis of candidate genes for generalized vitiligo supports XBP1, FOXP3, and TSLP. J Invest Dermatol (2010) 1.14
Naturally occurring melanomas in dogs as models for non-UV pathways of human melanomas. Pigment Cell Melanoma Res (2013) 1.11
A comparative analysis of FISH, RT-PCR, PCR, and immunohistochemistry for the diagnosis of mantle cell lymphomas. Mod Pathol (2002) 1.11
TCL1 and CLA expression in agranular CD4/CD56 hematodermic neoplasms (blastic NK-cell lymphomas) and leukemia cutis. Am J Clin Pathol (2004) 1.09
Genome-wide analysis identifies a quantitative trait locus in the MHC class II region associated with generalized vitiligo age of onset. J Invest Dermatol (2011) 1.08
CDKN2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma. Mod Pathol (2010) 1.06
Histologic and immunohistologic characterization of skin localization of myeloid disorders: a study of 173 cases. Am J Clin Pathol (2011) 1.06
Genome-wide analysis of cutaneous T-cell lymphomas identifies three clinically relevant classes. J Invest Dermatol (2010) 1.05
Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet (2013) 1.04
STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. Haematologica (2013) 1.04
Reliability of the histopathologic diagnosis of malignant melanoma in childhood. Arch Dermatol (2002) 1.02
Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation. Mol Cancer (2005) 1.02
Pregnancy and post-partum breast cancer: a prospective study. Anticancer Res (2008) 1.01
Methylene blue dye, an accurate dye for sentinel lymph node identification in early breast cancer. Anticancer Res (2009) 1.01
Autophagy inhibition cooperates with erlotinib to induce glioblastoma cell death. Cancer Biol Ther (2011) 1.00
Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients. Am J Surg Pathol (2014) 0.99
Detection and characterization of NF1 microdeletions by custom high resolution array CGH. J Mol Diagn (2009) 0.99
Acquired dermal melanocytosis of the back in a Caucasian woman. Am J Dermatopathol (2012) 0.99
Metastatic hidradenocarcinoma: efficacy of capecitabine. Arch Dermatol (2006) 0.97
Segmental vitiligo as the possible expression of cutaneous somatic mosaicism: implications for common non-segmental vitiligo. Pigment Cell Melanoma Res (2008) 0.96
Value of interphase FISH for the diagnosis of t(11:14)(q13;q32) on skin lesions of mantle cell lymphoma. Am J Clin Pathol (2002) 0.95
Dual stromelysin-3 function during natural mouse mammary tumor virus-ras tumor progression. Cancer Res (2003) 0.95
[Update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France]. Ann Pathol (2010) 0.94
Primary cutaneous T-cell lymphomas do not show specific NAV3 gene deletion or translocation. J Invest Dermatol (2008) 0.93
MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type. J Invest Dermatol (2012) 0.92
The relative levels of cyclin D1a and D1b alternative transcripts in mantle cell lymphoma may depend more on sample origin than on CCND1 polymorphism. Haematologica (2005) 0.92
p73alpha isoforms drive opposite transcriptional and post-transcriptional regulation of MYCN expression in neuroblastoma cells. Nucleic Acids Res (2008) 0.92
Ipilimumab in melanoma patients with brain metastasis: a retro-spective multicentre evaluation of thirty-eight patients. Acta Derm Venereol (2014) 0.91
Microdissection, mRNA amplification and microarray: a study of pleural mesothelial and malignant mesothelioma cells. Biochimie (2004) 0.91
IRF4 gene rearrangements define a subgroup of CD30-positive cutaneous T-cell lymphoma: a study of 54 cases. J Invest Dermatol (2009) 0.91
Mucosal intraepithelial T-lymphocytes in refractory celiac disease: a neoplastic population with a variable CD8 phenotype. Am J Surg Pathol (2008) 0.90
WNT5A encodes two isoforms with distinct functions in cancers. PLoS One (2013) 0.87
High resolution SNP array genomic profiling of peripheral T cell lymphomas, not otherwise specified, identifies a subgroup with chromosomal aberrations affecting the REL locus. Br J Haematol (2009) 0.86
Specific skin lesions in chronic myelomonocytic leukemia: a spectrum of myelomonocytic and dendritic cell proliferations: a study of 42 cases. Am J Surg Pathol (2012) 0.85
[The inter-university learning website: a national university network for online teaching of pathology]. Ann Pathol (2013) 0.85
XPC silencing in normal human keratinocytes triggers metabolic alterations through NOX-1 activation-mediated reactive oxygen species. Biochim Biophys Acta (2010) 0.85
Metabolomic profile of the adrenal gland: from physiology to pathological conditions. Endocr Relat Cancer (2013) 0.85
Follicular vitiligo: a new form of vitiligo. Pigment Cell Melanoma Res (2012) 0.84
Telomerase functions beyond telomere maintenance in primary cutaneous T-cell lymphoma. Blood (2014) 0.84
Sentinel lymph node biopsy in staging small (up to 15 mm) breast carcinomas. Results from a European multi-institutional study. Pathol Oncol Res (2007) 0.84
Hematoma-like metastases. J Am Acad Dermatol (2006) 0.83
BCL-2/JH translocation in peripheral blood lymphocytes of unexposed individuals: lack of seasonal variations in frequency and molecular features. Int J Cancer (2003) 0.83
Inactivation of p16INK4a/CDKN2A gene may be a diagnostic feature of large B cell lymphoma leg type among cutaneous B cell lymphomas. Virchows Arch (2008) 0.83
Neoplastic cells do not carry bcl2-JH rearrangements detected in a subset of primary cutaneous follicle center B-cell lymphomas. Am J Surg Pathol (2004) 0.82
Primary cutaneous follicular helper T-cell lymphoma: a new subtype of cutaneous T-cell lymphoma reported in a series of 5 cases. Arch Dermatol (2012) 0.81
BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer. Pathology (2014) 0.81
Clinical, histological and molecular follow-up of 60 patients with gastric marginal zone lymphoma of mucosa-associated lymphoid tissue. Virchows Arch (2005) 0.81
Large cell transformation of mycosis fungoides: tetraploidization within skin tumor large cells. Cancer Genet Cytogenet (2005) 0.81
Refinement of genotype-phenotype correlation in 18 patients carrying a 1q24q25 deletion. Am J Med Genet A (2015) 0.80
CD20 antigen may be expressed by reactive or lymphomatous cells of transformed mycosis fungoides: diagnostic and prognostic impact. Am J Surg Pathol (2013) 0.80
Metabolomic pattern of childhood neuroblastoma obtained by ¹H-high-resolution magic angle spinning (HRMAS) NMR spectroscopy. Pediatr Blood Cancer (2010) 0.80
Cutaneous hyphomycosis due to Paecilomyces lilacinus. Acta Derm Venereol (2012) 0.80
Reduced placental telomere length during pregnancies complicated by intrauterine growth restriction. PLoS One (2013) 0.80
[Late-onset vaccination-induced subcutaneous pseudolymphoma]. Ann Pathol (2008) 0.80
Automatized assessment of 1p36-19q13 status in gliomas by interphase FISH assay on touch imprints of frozen tumours. Acta Neuropathol (2006) 0.80
Validation of clinical prediction rules for a low probability of nonsentinel and extensive lymph node involvement in breast cancer patients. Am J Surg (2007) 0.79
Latent class analysis of a series of 717 patients with vitiligo allows the identification of two clinical subtypes. Pigment Cell Melanoma Res (2013) 0.79
Unknown multifocal ileal carcinoid revealed by (18)F-FDOPA PET/CT. J Clin Endocrinol Metab (2014) 0.79
Towards real-time metabolic profiling of a biopsy specimen during a surgical operation by 1H high resolution magic angle spinning nuclear magnetic resonance: a case report. J Med Case Rep (2012) 0.79
Assessment of tyrosinase variants and skin cancer risk in a large cohort of French subjects. J Dermatol Sci (2011) 0.78
Development and validation of the K-VSCOR for scoring Koebner's phenomenon in vitiligo/non-segmental vitiligo. Pigment Cell Melanoma Res (2013) 0.78
[Standards, Options and Recommendations 2004: good practice guidelines for second opinion in anatomic and surgical pathology in oncology (integral report)]. Bull Cancer (2004) 0.78
Urinary pS2/TFF1 levels in the management of hormonodependent breast carcinomas. Peptides (2004) 0.78